Invest and Sell Colossal Biosciences Stock

Colossal Biosciences Funding Rounds and Valuation

Funding History Chart

Funding Round Details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	01/31/2023	Series B	$150MM	$xx.xx	$1.01B	United States Innovative Technology Fund, Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, Jazs Ventures
Price per Share $xx.xx Shares Outstanding 34,134,353 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap N/A Key Investors United States Innovative Technology Fund, Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, Jazs Ventures
	03/09/2022	Series A	$60MM	$xx.xx	$256.49MM	Thomas Tull, At One Ventures, Untamed Planet, Animoca Brands, Breyer Capital, Animal Capital, Robert Nelsen, Paris Hilton, Bold Capital, First Light Capital Group, Boost VC, Jazz Ventures, Builders VC, Green Sands Equity, Draper Associates, Charles Hoskins
Price per Share $xx.xx Shares Outstanding 42,185,193 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap N/A Key Investors Thomas Tull, At One Ventures, Untamed Planet, Animoca Brands, Breyer Capital, Animal Capital, Robert Nelsen, Paris Hilton, Bold Capital, First Light Capital Group, Boost VC, Jazz Ventures, Builders VC, Green Sands Equity, Draper Associates, Charles Hoskins
	06/01/2021	Series Seed-2	$9.67MM	$xx.xx	$137.83MM	Thomas Tull, Breyer Capital, Draper Associates, Animal Capital, At One Ventures, Jazz Ventures, Jeff Wilke, Bold Capital, Global Space Ventures, Climate Capital, Winklevoss Capital, Liquid2 Ventures, Capital Factory, Tony Robbins, First Light Capital
Price per Share $xx.xx Shares Outstanding 8,000,000 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap N/A Key Investors Thomas Tull, Breyer Capital, Draper Associates, Animal Capital, At One Ventures, Jazz Ventures, Jeff Wilke, Bold Capital, Global Space Ventures, Climate Capital, Winklevoss Capital, Liquid2 Ventures, Capital Factory, Tony Robbins, First Light Capital
	06/01/2021	Series Seed-1	$8.36MM	$xx.xx	$137.83MM	Thomas Tull, Breyer Capital, Draper Associates, Animal Capital, At One Ventures, Jazz Ventures, Jeff Wilke, Bold Capital, Global Space Ventures, Climate Capital, Winklevoss Capital, Liquid2 Ventures, Capital Factory, Tony Robbins, First Light Capital
Price per Share $xx.xx Shares Outstanding 49,000,000 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap N/A Key Investors Thomas Tull, Breyer Capital, Draper Associates, Animal Capital, At One Ventures, Jazz Ventures, Jeff Wilke, Bold Capital, Global Space Ventures, Climate Capital, Winklevoss Capital, Liquid2 Ventures, Capital Factory, Tony Robbins, First Light Capital

Access Stock Price

Leadership & Board

Leadership

Adam Milne

Chief Operating Officer

Brian Beard, J.D.

Chief Legal Officer

Sam Singer, CFA

Chief Financial Officer

Sarah Grant

Chief of Staff

Peter Phillips

Chief Business Officer

Andrew Busey

Chief Product Officer

Board

Alexander Titus

Independent Advisor

Colossal Biosciences stock FAQs

Can you buy Colossal Biosciences stock?

As Colossal Biosciences is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Colossal Biosciences, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Colossal Biosciences stock?

To invest in a private company like Colossal Biosciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Colossal Biosciences stock?

Yes, you may sell the Colossal Biosciences stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Colossal Biosciences stock?

If you hold private company shares of Colossal Biosciences – whether as an employee or an early investor – Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Colossal Biosciences on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is Colossal Biosciences a public company?

No, Colossal Biosciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Colossal Biosciences’ stock price?

Colossal Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Colossal Biosciences private market stock price with Forge Data.

What is Colossal Biosciences’ stock ticker symbol?

Colossal Biosciences does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Colossal Biosciences’ news and media highlights

CBS News 10/20/2024

Scientists say they've made a breakthrough in efforts to bring back the extinct Tasmanian tiger

It's been decades since Australia's thylacine, known as the Tasmanian tiger, was declared extinct and scientists say they've made a breakthrough as they research ways to bring back the carnivore. Colossal Biosciences in a Thursday press release said its reconstructed thylacine genome is about 99.9% complete, with 45 gaps that they'll work to close through additional sequencing in the coming months. The company also isolated long RNA molecules from a 110-year-old preserved head, which was skinned and kept in ethanol.

Dallas Innovates 10/01/2024

Colossal Launches The Colossal Foundation with $50M for ‘BioVault’ Biobanking, Genetic Rescues, and More

The world’s first “de-extinction” company, Dallas-based Colossal Biosciences, has formed The Colossal Foundation, announcing $50 million in new funding and the initial flagship projects in its conservation agenda—including Colossal Biovault, “the world’s largest distributed biobanking initiative.” That biobanking effort is a hot topic these days. According to The Guardian, an international team of experts recently proposed to put a vault on the Moon filled with preserved bio-samples of our world’s most at-risk creatures.

LA Times 08/28/2024

Opinion: How bringing back the woolly mammoth could save species that still walk the Earth

As more species are pushed to the brink of extinction, conservationists are responding to our biodiversity crisis in new and sometimes controversial ways. One such novel approach could be described as the mammoth in the room: “de-extinction” technology that has the potential to protect and restore species on the brink of extinction and, more provocatively, those that disappeared from the planet long ago. We can avoid such innovation and the controversy that comes with it. But the reality is that many milestone moments in conservation have been contentious.

REUTERS 04/25/2023

De-extinction: Bringing animal species back from the brink

Inside the National Black-Footed Ferret Conservation Center, in Carr, Colorado, Dr. Della Garelle, a veterinarian with the U.S. Fish and Wildlife Service, is leading the effort to bring one of America's most endangered species back from the brink of extinction. "Sunday Morning" was invited to witness Garelle's physical exams of the ferrets ahead of breeding season. "We gotta check out the goods because, well, it's a breeding program, right? So, we can't be shy," she said. It was only a few decades ago that reproduction wasn't even thought possible; the species was believed to be extinct, due to habitat loss and disease. But in 1981 the federal government tracked down the only known colony, and started this breeding program, with just seven ferrets.

Browse More Insights

Updated on: Nov 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Colossal Biosciences Stock

Register To Buy and Sell Private Company Shares

Enterprise Value

Access Colossal Biosciences’ valuation and stock price.

Colossal Biosciences Stock Price